Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial

In PARADIGM-HF, LCZ696 was shown to reduce cardiovascular death, heart failure hospitalization and all-cause mortality compared with enalapril. As the majority of patients maintained the target dose of LCZ696 200 mg bid (mean 375 mg daily for LCZ696) and enalapril 10 mg bid (18.9 mg daily for enalapril) during the study, we investigated whether LCZ696 confers similar benefit relative to enalapril in patients who could not tolerate target doses.

http://www.onlinejcf.com/article/S1071-9164(15)00266-3/abstract?rss=yes

Source: Journal of Cardiac Failure - July 31, 2015 Category: Cardiology Authors: Orly Vardeny, Brian Claggett, John J.V. McMurray, Milton Packer, Jean Rouleau, John R. Teerlink, Michael Zile, Karl Swedberg, Martin Lefkowitz, Victor Shi Tags: Rapid-Fire Abstracts I Source Type: research